膀胱癌・尿管癌治療薬開発パイプラインレビュー2017

◆英語タイトル:Bladder and Ureter Cancer Drug Development Pipeline Review, 2017
◆商品コード:GBIHC027IDB
◆発行会社(リサーチ会社):GBI Research
◆発行日:2017年12月
◆ページ数:150
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥439,450見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥878,900見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,318,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GBI Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017
Summary

This report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.

Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. This pipeline is far smaller; there are a total of nine products in development for this indication, by six companies and two academic institutions.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Bladder and Ureter Cancer Report Coverage 9
2.2 Ureter Cancer – Overview 9
2.3 Bladder Cancer – Overview 9
3 Therapeutics Development 10
3.1 Ureter Cancer 10
3.2 Bladder Cancer 14
4 Therapeutics Assessment 34
4.1 Ureter Cancer 34
4.2 Bladder Cancer 41
5 Companies Involved in Therapeutics Development 58
5.1 Ureter Cancer 58
5.2 Bladder Cancer 61
6 Dormant Projects 125
6.1 Bladder Cancer 125
7 Discontinued Products 131
7.1 Bladder Cancer 131
8 Product Development Milestones 133
8.1 Ureter Cancer 133
8.2 Bladder Cancer 135
9 Appendix 149
9.1 Methodology 149
9.2 Coverage 149
9.3 Secondary Research 149
9.4 Primary Research 149
9.5 Expert Panel Validation 149
9.6 Contact Us 150
9.7 Disclaimer 150

1.1 List of Tables
Table 1: Number of Products under Development for Ureter Cancer 10
Table 2: Number of Products under Development by Companies, Ureter Cancer 11
Table 3: Number of Products under Development by Universities/Institutes, Ureter Cancer 12
Table 4: Products under Development by Companies, Ureter Cancer 13
Table 5: Products under Development by Universities/Institutes, Ureter Cancer 13
Table 6: Number of Products under Development for Bladder Cancer 14
Table 7: Number of Products under Development by Companies, Bladder Cancer 16
Table 8: Number of Products under Development by Universities/Institutes, Bladder Cancer 21
Table 9: Products under Development by Companies, Bladder Cancer 22
Table 10: Products under Development by Universities/Institutes, Bladder Cancer 32
Table 11: Number of Products by Stage and Target, Ureter Cancer 35
Table 12: Number of Products by Stage and Mechanism of Action, Ureter Cancer 37
Table 13: Number of Products by Stage and Route of Administration, Ureter Cancer 39
Table 14: Number of Products by Stage and Molecule Type, Ureter Cancer 40
Table 15: Number of Products by Stage and Target, Bladder Cancer 42
Table 16: Number of Products by Stage and Mechanism of Action, Bladder Cancer 48
Table 17: Number of Products by Stage and Route of Administration, Bladder Cancer 55
Table 18: Number of Products by Stage and Molecule Type, Bladder Cancer 57
Table 19: Ureter Cancer – Pipeline by Altor BioScience Corp 58
Table 20: Ureter Cancer – Pipeline by Eisai Co Ltd 58
Table 21: Ureter Cancer – Pipeline by Exelixis Inc 59
Table 22: Ureter Cancer – Pipeline by GlaxoSmithKline Plc 59
Table 23: Ureter Cancer – Pipeline by MedImmune LLC 60
Table 24: Ureter Cancer – Pipeline by Merck & Co Inc 60
Table 25: Bladder Cancer – Pipeline by 4SC AG 61
Table 26: Bladder Cancer – Pipeline by Abivax SA 61
Table 27: Bladder Cancer – Pipeline by Adaptimmune Therapeutics Plc 62
Table 28: Bladder Cancer – Pipeline by ADC Therapeutics Sarl 62
Table 29: Bladder Cancer – Pipeline by Altor BioScience Corp 63
Table 30: Bladder Cancer – Pipeline by AndroScience Corp 63
Table 31: Bladder Cancer – Pipeline by ANP Technologies Inc 64
Table 32: Bladder Cancer – Pipeline by APIM Therapeutics AS 64
Table 33: Bladder Cancer – Pipeline by Archivel Farma SL 65
Table 34: Bladder Cancer – Pipeline by Argos Therapeutics Inc 65
Table 35: Bladder Cancer – Pipeline by Arno Therapeutics Inc 66
Table 36: Bladder Cancer – Pipeline by Array BioPharma Inc 66
Table 37: Bladder Cancer – Pipeline by Asana BioSciences LLC 67
Table 38: Bladder Cancer – Pipeline by Asieris Pharmaceuticals Co Ltd 67
Table 39: Bladder Cancer – Pipeline by Astellas Pharma Inc 68
Table 40: Bladder Cancer – Pipeline by Astex Pharmaceuticals Inc 68
Table 41: Bladder Cancer – Pipeline by AstraZeneca Plc 69
Table 42: Bladder Cancer – Pipeline by AVEO Pharmaceuticals Inc 69
Table 43: Bladder Cancer – Pipeline by Bavarian Nordic A/S 70
Table 44: Bladder Cancer – Pipeline by Bayer AG 70
Table 45: Bladder Cancer – Pipeline by Biocad 71
Table 46: Bladder Cancer – Pipeline by BioCancell Ltd 71
Table 47: Bladder Cancer – Pipeline by Biohaven Pharmaceutical Holding Company Ltd 72
Table 48: Bladder Cancer – Pipeline by Biomics Biotechnologies Co Ltd 72
Table 49: Bladder Cancer – Pipeline by Biotest AG 73
Table 50: Bladder Cancer – Pipeline by Boehringer Ingelheim GmbH 73
Table 51: Bladder Cancer – Pipeline by Bristol-Myers Squibb Co 74
Table 52: Bladder Cancer – Pipeline by Celgene Corp 74
Table 53: Bladder Cancer – Pipeline by Celldex Therapeutics Inc 75
Table 54: Bladder Cancer – Pipeline by Celprogen Inc 75
Table 55: Bladder Cancer – Pipeline by Celsion Corp 76
Table 56: Bladder Cancer – Pipeline by Celyad SA 76
Table 57: Bladder Cancer – Pipeline by Cleveland BioLabs Inc 77
Table 58: Bladder Cancer – Pipeline by Cold Genesys Inc 77
Table 59: Bladder Cancer – Pipeline by Corvus Pharmaceuticals Inc 78
Table 60: Bladder Cancer – Pipeline by CytomX Therapeutics Inc 78
Table 61: Bladder Cancer – Pipeline by Cytori Therapeutics Inc 79
Table 62: Bladder Cancer – Pipeline by Daiichi Sankyo Co Ltd 79
Table 63: Bladder Cancer – Pipeline by Eisai Co Ltd 80
Table 64: Bladder Cancer – Pipeline by Eleven Biotherapeutics Inc 80
Table 65: Bladder Cancer – Pipeline by Eli Lilly and Co 81
Table 66: Bladder Cancer – Pipeline by Elsalys Biotech SAS 82
Table 67: Bladder Cancer – Pipeline by EpiThany Inc 82
Table 68: Bladder Cancer – Pipeline by Esperance Pharmaceuticals Inc 83
Table 69: Bladder Cancer – Pipeline by Exelixis Inc 83
Table 70: Bladder Cancer – Pipeline by Exicure Inc 84
Table 71: Bladder Cancer – Pipeline by F. Hoffmann-La Roche Ltd 84
Table 72: Bladder Cancer – Pipeline by Five Prime Therapeutics Inc 85
Table 73: Bladder Cancer – Pipeline by Gene Signal International SA 85
Table 74: Bladder Cancer – Pipeline by Genentech Inc 86

【掲載企業】

4SC AG
Abivax SA
Adaptimmune Therapeutics Plc
ADC Therapeutics Sarl
Altor BioScience Corp
AndroScience Corp
ANP Technologies Inc
APIM Therapeutics AS
Archivel Farma SL
Argos Therapeutics Inc
Arno Therapeutics Inc
Array BioPharma Inc
Asana BioSciences LLC
Asieris Pharmaceuticals Co Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bavarian Nordic A/S
Bayer AG
Biocad
BioCancell Ltd
Biohaven Pharmaceutical Holding Company Ltd
Biomics Biotechnologies Co Ltd
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Celgene Corp
Celldex Therapeutics Inc
Celprogen Inc
Celsion Corp
Celyad SA
Cleveland BioLabs Inc
Cold Genesys Inc
Corvus Pharmaceuticals Inc
CytomX Therapeutics Inc
Cytori Therapeutics Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
Eleven Biotherapeutics Inc
Eli Lilly and Co
Elsalys Biotech SAS
EpiThany Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Gene Signal International SA
Genentech Inc
Genmab A/S
GlaxoSmithKline Plc
H3 Biomedicine Inc
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
HitGen LTD
Horizon Pharma Plc
Immunocore Ltd
Immunomedics Inc
Immupharma Plc
Imugene Ltd
Incanthera Ltd
Incyte Corp
Innovation Pharmaceuticals Inc
InteRNA Technologies BV
Iovance Biotherapeutics Inc
Johnson & Johnson
Kite Pharma Inc
Laboratoires Pierre Fabre SA
LipoMedix Pharmaceutical Inc
Loxo Oncology Inc
Lycera Corp
MacroGenics Inc
Marina Biotech Inc
MaxiVAX SA
Medicenna Therapeutics Corp
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mirati Therapeutics Inc
Moleculin Biotech Inc
MTG Biotherapeutics Inc
NanoCarrier Co Ltd
NantKwest Inc
Nektar Therapeutics
Novartis AG
OncoTherapy Science Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Optimum Therapeutics LLC
Oxford BioTherapeutics Ltd
Pfizer Inc
Pharma Mar SA
Philogen SpA
Pieris Pharmaceuticals Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Provecs Medical GmbH (Inactive)
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Rexahn Pharmaceuticals Inc
Samyang Holdings Corp
Sanofi
Sareum Holdings Plc
Shionogi & Co Ltd
Sierra Oncology Inc
Sillajen Biotherapeutics
Sitka Biopharma Inc
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Stemline Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Taiwan Liposome Company Ltd
Taris Biomedical LLC
Theralase Technologies Inc
Tocagen Inc
Tolero Pharmaceuticals Inc
Transgene SA
UroGen Pharma Ltd
Vaccibody AS
Vakzine Projekt Management GmbH
Vault Pharma Inc
Vaxeal Holding SA
Vaxiion Therapeutics Inc
Viralytics Ltd
Vyriad Inc
Zymeworks Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[膀胱癌・尿管癌治療薬開発パイプラインレビュー2017]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆